Bimatoprost 0.01% ophthalmic solution

DRUG8 trials

Sponsors

Allergan, Alcon Research

Conditions

GlaucomaGlaucoma, Open-AngleOcular HypertensionOpen-Angle Glaucoma

Phase 2

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

CompletedNCT00652496

AllerganGlaucoma, Ocular Hypertension

Start: 2005-01-31End: 2005-05-31Updated: 2008-04-03

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

CompletedNCT00651859

AllerganGlaucoma, Ocular Hypertension

Start: 2002-11-30End: 2004-01-31Updated: 2008-04-03

Phase 4

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

CompletedNCT01298700

AllerganGlaucoma, Ocular Hypertension

Start: 2011-05-31End: 2016-12-06Updated: 2018-09-17

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

CompletedNCT01464424

Alcon ResearchGlaucoma, Ocular Hypertension, Open-Angle Glaucoma

Start: 2011-10-31End: 2012-06-30Updated: 2013-09-13

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

CompletedNCT01664039

Alcon ResearchGlaucoma, Ocular Hypertension

Start: 2012-09-30End: 2014-06-30Updated: 2015-08-03

Unknown Phase

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

CompletedNCT01489670

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2011-09-30End: 2013-03-31Updated: 2014-03-28

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

CompletedNCT01568008

AllerganOcular Hypertension, Open-Angle Glaucoma

Start: 2011-10-31End: 2012-09-30Updated: 2013-09-20

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

CompletedNCT01589510

AllerganGlaucoma, Open-Angle, Ocular Hypertension

Start: 2012-04-30End: 2013-02-28Updated: 2014-06-13

Related Papers

Late-day intraocular pressure-lowering efficacy and tolerability of travoprost 0.004% versus bimatoprost 0.01% in patients with open-angle glaucoma or ocular hypertension: a randomized trial.

2014-11-287 citations